Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Cardiovascular Toxicology, 19 (5), 441450
Top image: Skull and jaw from the remains used in the study
Archived from the original on 4 July 2024
CHANTIX has also been studied in postmarketing trials including (1) a trial conducted in patients with chronic obstructive pulmonary disease (COPD), (2) a trial conducted in generally healthy patients (similar to those in the premarketing studies) in which they were allowed to select a quit date between days 8 and 35 of treatment ("alternative quit date instruction trial"), (3) a trial conducted in patients who did not succeed in stopping smoking during prior CHANTIX therapy, or who relapsed after treatment ("re-treatment trial"), (4) a trial conducted in patients with stable cardiovascular disease, (5) a trial conducted in patients with stable schizophrenia or schizoaffective disorder, (6) a trial conducted in patients with major depressive disorder, (7) a postmarketing neuropsychiatric safety outcome trial in patients without or with a history of psychiatric disorder, (8) a non-treatment extension of the postmarketing neuropsychiatric safety outcome trial that assessed CV safety, (9) a trial in patients who were not able or willing to quit abruptly and who were instructed to quit gradually ("gradual approach to quitting smoking trial")
The one to the left, NOW KING is Ultra Rare and hard to find and depending on condition can be worth $1000 or more!
25% Off While Supplies Last OFFER EXPIRES MARCH 31, 2026
US$ 28.45
US$ 23.60
US$ 25.85
US$ 28.14
US$ 29.62
US$ 25.78
